This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration approaches: the SARS-CoV-2 mRNA vaccine alone, the influenza vaccine alone, and the co-administration of both vaccines.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
36
Administering a booster dose of the bivalent mRNA vaccine BNT162b2
Administering a VaxigripTetra™
Faculty of Medicine, Prince of Songkla University
Songkhla, Thailand
Geometric Mean (GM) of Interferon-gamma (IFN-γ) Response Against the SARS-CoV-2 Virus at Baseline
IFN-γ response against the SARS-CoV-2 virus, measured by the ELISpot assay
Time frame: Before vaccination
Geometric Mean (GM) of Interferon-gamma (IFN-γ) Response Against the SARS-CoV-2 Virus at 4 Weeks
IFN-γ response against the SARS-CoV-2 virus, measured by the ELISpot assay
Time frame: 4 weeks post vaccination
Geometric Mean (GM) of IgG Response Against the SARS-CoV-2 Virus at Baseline
IgG response against the SARS-CoV-2 virus, measured by ELISA.
Time frame: before vaccination
Geometric Mean (GM) of IgG Response Against the SARS-CoV-2 Virus at 4 Weeks
IgG response against the SARS-CoV-2 virus, measured by ELISA.
Time frame: 4 weeks post vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.